DuLac Farmaceutici, an Italian pharmaceutical company, is accelerating its U.S. market expansion with two strategic moves: the availability of its products on OneLavi.com and its participation in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, scheduled for September 14-17 in Palm Beach Gardens, Florida. These initiatives mark a significant step in the company's broader strategy to establish a substantial presence in the United States, following its initial success on Amazon.
The company's U.S. expansion is not relying on a single channel. Instead, DuLac is building a multi-faceted approach that combines existing Amazon demand, new e-commerce availability through OneLavi, and direct engagement with retailers and distribution partners at ECRM. This comprehensive strategy is designed to introduce the brand to a wider American audience and secure long-term growth.
Gabriele Bollani, Founder and CEO of DuLac Farmaceutici, emphasized the importance of these developments: "ECRM comes at an important time for DuLac because we are making a major commitment to the U.S. market. Amazon has demonstrated that American consumers are responding to our products, OneLavi gives us another important U.S. channel, and now we are ready to introduce DuLac to major retailers and build the partnerships that can take our expansion to the next level."
DuLac's entry into this phase is backed by strong consumer validation on Amazon. The company's Arnica Gel 98% has garnered more than 13,000 customer reviews with an average 4.5-star rating, while its Dinaven line has received over 4,000 reviews with an average 4.6-star rating. These figures underscore the growing demand for DuLac's products among American consumers.
The addition of OneLavi as a distribution partner provides another platform for DuLac to showcase its Made in Italy portfolio. By making its products available on OneLavi.com, the company broadens its e-commerce reach and offers American consumers another convenient way to purchase its wellness solutions.
Participation in the ECRM session adds a crucial business-to-business dimension to DuLac's expansion. During the event, the company will engage in scheduled meetings with buyers from major health, specialty, food, drug, and mass retail channels. These meetings present an opportunity to introduce DuLac's Italian-developed product portfolio, pharmaceutical heritage, and advanced manufacturing capabilities to potential U.S. retail partners. Among the products highlighted will be the high-concentration Arnica Gel 98% range and the Dinaven and Diosmin lines.
For DuLac, the goal is not merely to gain additional points of distribution but to establish relationships that can support a much larger and more diversified U.S. retail presence. The company aims to leverage ECRM to build partnerships that will facilitate its national expansion strategy.
DuLac brings over 30 years of pharmaceutical industry expertise and pharmacy-channel experience in Italy to its U.S. efforts. Its product development and manufacturing capabilities include proprietary technologies such as the Arnica Montana Arricchita™ project, indoor vertical farming, micronized Diosmin MPFF technology, and solvent-free Supercritical CO₂ Extraction. All manufacturing adheres to internationally recognized GMP and ISO quality frameworks.
This combination of Italian pharmaceutical heritage, research, advanced production technologies, established Amazon consumer demand, and growing U.S. distribution forms the foundation for DuLac's next stage of growth. With Amazon already established, OneLavi now live, and scheduled meetings with major retail buyers planned through ECRM, DuLac is transitioning from initial U.S. market development to a broader national expansion strategy.
The company's objective is to build a diversified U.S. presence across e-commerce, retail, wholesale, and other distribution channels, introducing more American consumers to the DuLac brand and its Italian-developed product portfolio. As DuLac moves forward, it is poised to become a significant player in the U.S. wellness market, bringing its pharmaceutical-grade products to a wider audience.
